Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03943498 · ClinicalTrials.gov registry record · Early Phase 1
Fingolimod in Treating Patients With Chemotherapy-Induced Neuropathy
A Early Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 2
- Enrollment target
NCT03943498: Completed Early Phase 1 study, sponsored by Mayo Clinic.
NCT03943498 is a Early Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 2 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03943498, a Early Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This early phase I trial studies how well fingolimod works in treating patients with chemotherapy-induced nerve pain (neuropathy). Fingolimod acts by suppressing immune reactions in the brain. This study is being done to see if fingolimod can reduce neuropathy caused by chemotherapy.
Primary Outcome
Will be obtained from the 6 individual Quality of Life Questionnaire - Chemotherapy-Induced Peripheral Neuropathy 20 (QLQ-CIPN20) questions that quantify numbness, tingling, and pain in the fingers (or hands) and toes (or feet). The hypothesis will be tested with the two-sided one-sample t-test at a significance level of 10% reduction. In the event that the distribution of the within-patients change from baseline in total sensory neuropathy scores is not approximately normally distributed, then
Interventions
- OTHER Questionnaire Administration
- DRUG Fingolimod
- DRUG Fingolimod Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2019-05-24 |
| Est. Completion | 2020-12-10 |
| Phase | Early Phase 1 |
What the finished NCT03943498 record still lists
NCT03943498 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 3 interventions - of which Questionnaire Administration is the first listed.
NCT03943498 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03943498 about?
NCT03943498 is a clinical study titled "Fingolimod in Treating Patients With Chemotherapy-Induced Neuropathy". This early phase I trial studies how well fingolimod works in treating patients with chemotherapy-induced nerve pain (neuropathy). Fingolimod acts by suppressing immune reactions in the brain. This study is being done to see if fingolimod can reduce neuropathy caused by chemotherapy.
What is the current status of trial NCT03943498?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 2 participants. The study started on 2019-05-24. Estimated completion is 2020-12-10.
What interventions are being tested in trial NCT03943498?
The interventions under investigation include: Questionnaire Administration (OTHER), Fingolimod (DRUG), Fingolimod Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT03943498?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03943498's enrollment target sits among peer trials
2 1974th of 2000 higher than 16 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI